The ability to monitor drugs, metabolites, hormones, and other
biomarkers in situ in the body would greatly advance both clinical
practice and biomedical research. To this end, we are developing electrochemical
aptamer-based (EAB) sensors, a platform technology able to perform
real-time, in vivo monitoring of specific molecules irrespective of
their chemical or enzymatic reactivity. An important obstacle to the
deployment of EAB sensors in the challenging environments found in
the living body is signal drift, whereby the sensor signal decreases
over time. To date, we have demonstrated a number of approaches by
which this drift can be corrected sufficiently well to achieve good
measurement precision over multihour in vivo deployments. To achieve
a much longer in vivo measurement duration, however, will likely require
that we understand and address the sources of this effect. In response,
here, we have systematically examined the mechanisms underlying the
drift seen when EAB sensors and simpler, EAB-like devices are challenged
in vitro at 37 °C in whole blood as a proxy for in vivo conditions.
Our results demonstrate that electrochemically driven desorption of
a self-assembled monolayer and fouling by blood components are the
two primary sources of signal loss under these conditions, suggesting
targeted approaches to remediating this degradation and thus improving
the stability of EAB sensors and other, similar electrochemical biosensor
technologies when deployed in the body.